RxDoctor Payments Data

Abdullah Pervaiz, MD

Interventional Cardiology · Florence, SCNPI 1609308691

Payments from drug & device makers

$2,124in general payments, 2019–2025

Across 24 payments — averaging $88.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$803
  • AstraZeneca$429
  • Medtronic$346
  • Johnson & Johnson$109
  • Amgen$105
  • Inari Medical, Inc.$84
  • plus $248 from 7 others

What the payments were for

  • Food & beverage$1,47970%
  • Education$64530%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,124 in reported general payments places this provider in the 10th percentile of 117 interventional cardiology providers in South Carolina.

See all interventional cardiology providers in South Carolina

Medicare billing

Part B allowed, 2024
$39,295
Medicare patients
302
Services billed
658

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BrilintaTicagrelor97$54,078
EliquisApixaban18$16,194
EntrestoSacubitril/Valsartan14$9,592
Repatha SureclickEvolocumab12$7,021
ClopidogrelClopidogrel Bisulfate151$2,325
Metoprolol Succinate128$962
Rosuvastatin Calcium29$440
Atorvastatin Calcium48$371
Amlodipine Besylate106$296
Losartan Potassium23$196
Carvedilol41$190
Isosorbide Mononitrate ErIsosorbide Mononitrate21$172
Furosemide42$142
Lisinopril16$88

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBrilinta$429$54,07897 claims
PfizerEliquis$27$16,19418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 117 interventional cardiology providers in South Carolina.

Other interventional cardiology in Florence

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →